190
Participants
Start Date
July 31, 2013
Primary Completion Date
September 30, 2017
Study Completion Date
April 30, 2023
EBV
This study arm will undergo EBV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
Optimal Medical Management
This study arm will receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
University Medical Center Groningen, Groningen
University of Pittsburgh Medical Center, Pittsburgh
Temple University Hospital, Philadelphia
Duke University Medical Center, Durham
Medical University of South Carolina, Charleston
Orlando Health, Orlando
The University of Alabama at Birmingham, Birmingham
University of Louisville Research Foundation, Louisville
Cleveland Clinic, Cleveland
Houston Methodist Hospital, Houston
Arizona Pulmonary Specialists, Phoenix
University of Southern California, Los Angeles
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance
El Camino Hospital, Mountain View
University of California, San Francisco, San Francisco
Stanford University, Stanford
University of California at Davis Medical Center, Sacramento
Beth Israel Deaconess Medical Center, Boston
Hospital de Clinicas Porto Alegre, Porto Alegre
INCOR - Hospital das Clinicas de Faculdade de Medicine da USP, São Paulo
Bristol Royal Infirmary, Bristol
University Hospital Llandough and University Hospital of Wales, Cardiff
Royal Brompton & Harefield NHS Foundation Trust, London
Pulmonx Corporation
INDUSTRY